Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R M Bukowski

Showing results (131-140 of 167) with videos related to

Pageof 17
Sort By:
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|May 4, 1993
Phase I trial of recombinant granulocyte-macrophage colony-stimulating factor in patients with lung cancer: clinical and immunologic effectsR M Bukowski, S Murthy, D McLain, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|February 1, 1994
Characterization of tumor-infiltrating lymphocyte subsets from human renal cell carcinoma: specific reactivity defined by cytotoxicity, interferon-gamma secretion, and proliferationJ H Finke, P Rayman, L Hart, et al.
Cancer Research|August 15, 1991
Clinical results and characterization of tumor-infiltrating lymphocytes with or without recombinant interleukin 2 in human metastatic renal cell carcinomaR M Bukowski, W Sharfman, S Murthy, et al.
Molecular Pharmacology|November 26, 1999
Altered drug interaction and regulation of topoisomerase IIbeta: potential mechanisms governing sensitivity of HL-60 cells to amsacrine and etoposideD R Grabowski, K A Holmes, M Aoyama, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 1994
Phase I trial of subcutaneous recombinant macrophage colony-stimulating factor: clinical and immunomodulatory effectsR M Bukowski, G T Budd, J A Gibbons, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|July 1, 1993
Immunomodulatory effects of recombinant interleukin-3 treatment on human alveolar macrophages and monocytesM J Thomassen, J M Antal, M J Connors, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1987
5-Fluorouracil and folinic acid in the treatment of metastatic colorectal cancer: a randomized comparison. A Southwest Oncology Group StudyG T Budd, T R Fleming, R M Bukowski, et al.
Arthritis and Rheumatism|August 1, 1984
T cell lymphoma occurring in Sjögren's syndromeW S Wilke, R R Tubbs, R M Bukowski, et al.
Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research|May 22, 2001
Randomized multicenter phase II trial of subcutaneous recombinant human interleukin-12 versus interferon-alpha 2a for patients with advanced renal cell carcinomaR J Motzer, A Rakhit, J A Thompson, et al.
Cancer Treatment Reports|July 1, 1983
High-dose chlorozotocin in lung cancer: a Southwest Oncology Group Phase II StudyC D Haas, R L Stephens, R M Bukowski, et al.
Pageof 17

Showing results (131-140 of 167) with videos related to

Sort By:
Pageof 17
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|May 4, 1993
Phase I trial of recombinant granulocyte-macrophage colony-stimulating factor in patients with lung cancer: clinical and immunologic effectsR M Bukowski, S Murthy, D McLain, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|February 1, 1994
Characterization of tumor-infiltrating lymphocyte subsets from human renal cell carcinoma: specific reactivity defined by cytotoxicity, interferon-gamma secretion, and proliferationJ H Finke, P Rayman, L Hart, et al.
Cancer Research|August 15, 1991
Clinical results and characterization of tumor-infiltrating lymphocytes with or without recombinant interleukin 2 in human metastatic renal cell carcinomaR M Bukowski, W Sharfman, S Murthy, et al.
Molecular Pharmacology|November 26, 1999
Altered drug interaction and regulation of topoisomerase IIbeta: potential mechanisms governing sensitivity of HL-60 cells to amsacrine and etoposideD R Grabowski, K A Holmes, M Aoyama, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 1994
Phase I trial of subcutaneous recombinant macrophage colony-stimulating factor: clinical and immunomodulatory effectsR M Bukowski, G T Budd, J A Gibbons, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|July 1, 1993
Immunomodulatory effects of recombinant interleukin-3 treatment on human alveolar macrophages and monocytesM J Thomassen, J M Antal, M J Connors, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1987
5-Fluorouracil and folinic acid in the treatment of metastatic colorectal cancer: a randomized comparison. A Southwest Oncology Group StudyG T Budd, T R Fleming, R M Bukowski, et al.
Arthritis and Rheumatism|August 1, 1984
T cell lymphoma occurring in Sjögren's syndromeW S Wilke, R R Tubbs, R M Bukowski, et al.
Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research|May 22, 2001
Randomized multicenter phase II trial of subcutaneous recombinant human interleukin-12 versus interferon-alpha 2a for patients with advanced renal cell carcinomaR J Motzer, A Rakhit, J A Thompson, et al.
Cancer Treatment Reports|July 1, 1983
High-dose chlorozotocin in lung cancer: a Southwest Oncology Group Phase II StudyC D Haas, R L Stephens, R M Bukowski, et al.
Pageof 17